WHAT IS A SINGLE IMMEDIATE INTRAVESICAL CHEMOTHERAPY INSTILLATION?
İçerik yapay zeka ile optimize edilmiştir
Single Immediate Intravesical Chemotherapy (SI)
Single Immediate Intravesical Chemotherapy (SI) is a specialized preventive treatment administered directly into the bladder following a Transurethral Resection of Bladder Tumor (TURBT). This procedure is designed for appropriately selected patients to eliminate microscopic cancer cells that may remain post-surgery. By targeting these residual cells, the treatment significantly reduces the risk of tumor recurrence.
According to the 2026 European Association of Urology (EAU) Guidelines, administering a single dose of intravesical chemotherapy within the first 24 hours after TURBT is an evidence-based strategy. This approach is particularly effective for patients diagnosed with non-muscle-invasive bladder cancer (NMIBC), ensuring a proactive start to the recovery process.
What is Single Immediate Intravesical Chemotherapy Instillation?
Unlike systemic treatments, intravesical chemotherapy involves placing the medication directly into the bladder through a catheter rather than a vein. This localized approach ensures that the treatment targets the bladder lining specifically while minimizing systemic side effects on the rest of the body.
The medication remains inside the bladder for a predetermined period. After this duration, it is either drained through the catheter or passed naturally during urination. This method ensures maximum contact between the medication and any potential residual cancer cells.
Why is the Procedure Performed?
After a TURBT procedure, there is a possibility that microscopic cancer cells remain in the bladder or become re-implanted onto the bladder lining. The primary objectives of a single immediate instillation are:
- Eliminating residual microscopic cancer cells that are invisible to the naked eye.
- Preventing tumor cell implantation on the surgical site or healthy tissue.
- Reducing the overall risk of bladder cancer recurrence.
Medications Used in the Treatment
International guidelines specify certain medications for this procedure. The choice of drug is determined by the patient's clinical profile and pathological findings. The most commonly used medications include:
| Medication | Application Method | Purpose |
|---|---|---|
| Mitomycin C | Intravesical Instillation | Preventing Recurrence |
| Gemcitabine | Intravesical Instillation | Targeted Cell Destruction |
Who is a Suitable Candidate?
This treatment is not universal and must be individualized. It is primarily considered for:
- Patients with low-risk NMIBC.
- Selected patients with intermediate-risk NMIBC.
- Individuals whose surgical findings allow for safe immediate instillation.
Contraindications: Who Should Not Receive This Treatment?
Patient safety is the highest priority. Single immediate intravesical chemotherapy is generally avoided in the following clinical situations:
- Suspected bladder perforation during surgery.
- Significant postoperative bleeding (gross hematuria).
- Suspected muscle-invasive bladder cancer (MIBC).
- Any clinical condition where intravesical treatment may pose a safety risk.
How is the Procedure Performed?
The procedure is seamless and does not require additional surgery. The chemotherapy medication is administered through the urinary catheter immediately after the TURBT procedure is completed. The solution is held in the bladder for a specific time and then safely drained or voided.
The EAU 2026 Key Message for Patients
The 2026 EAU Guidelines emphasize that a single instillation within the first 24 hours can significantly lower recurrence rates. However, the decision must be based on a comprehensive evaluation of surgical findings, the pathology report, and the patient’s individual risk profile.
Single Immediate Intravesical Chemotherapy with Assoc. Prof. Dr. Serdar Yalçın
Assoc. Prof. Dr. Serdar Yalçın provides expert intravesical chemotherapy treatments in Bodrum, Türkiye, strictly adhering to the latest European Association of Urology (EAU) Guidelines. Each treatment plan is individualized based on pathological findings, risk classification, and surgical outcomes.
Patients from Bodrum, the Muğla region, and across the globe seek consultation for:
- Bladder cancer diagnosis and second opinions.
- Personalized treatment planning.
- Evidence-based, patient-centered care and close follow-up.
Frequently Asked Questions (FAQ)
Is this the same as intravenous chemotherapy?
No. The medication is placed directly inside the bladder and is not administered through the bloodstream, which reduces systemic side effects.
Does every patient receive this treatment?
No. The decision depends on specific tumor characteristics, surgical findings, and the patient's unique risk profile.
Is one treatment enough?
For some patients, a single dose is sufficient. Others may require further treatments, such as BCG immunotherapy, depending on the pathology results.
